Drugs / etakafusp alfa
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07300475 | Aug 2026 → May 2030 expected | triple-negative breast carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07037758 | Sep 2025 → Mar 2028 expected | small cell lung carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT05653882 | Jan 2023 → Aug 2026 overdue | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, renal cell carcinoma | Asher Biotherapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | etakafusp alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05653882 ↗ |
| Known as | AB248 | “Intravenous infusion of etakafusp alfa (AB248): CD8+ T cell selective interleukin-2 investigational drug” NCT05653882 ↗ |
| Modality | Protein / enzyme biologic | “CD8+ T cell selective interleukin-2 investigational drug” NCT05653882 ↗ |
| Route | Intravenous | “Intravenous infusion of etakafusp alfa (AB248)” NCT05653882 ↗ |